JP2017525777A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017525777A5 JP2017525777A5 JP2017530962A JP2017530962A JP2017525777A5 JP 2017525777 A5 JP2017525777 A5 JP 2017525777A5 JP 2017530962 A JP2017530962 A JP 2017530962A JP 2017530962 A JP2017530962 A JP 2017530962A JP 2017525777 A5 JP2017525777 A5 JP 2017525777A5
- Authority
- JP
- Japan
- Prior art keywords
- medicament
- subject
- alkyl
- compound according
- need
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 25
- 239000003814 drug Substances 0.000 claims 23
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 125000003118 aryl group Chemical group 0.000 claims 9
- 125000006693 (C2-C9) heterocyclyl group Chemical group 0.000 claims 8
- 125000004452 carbocyclyl group Chemical group 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 claims 3
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 3
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims 3
- 150000002431 hydrogen Chemical class 0.000 claims 3
- -1 pyrazolyl ethyl Chemical group 0.000 claims 3
- 208000023504 respiratory system disease Diseases 0.000 claims 3
- XTNOEYFQXCQKLC-UHFFFAOYSA-N 18-(oxiren-2-yl)octadeca-15,17-dienoic acid Chemical compound C1=C(C=CC=CCCCCCCCCCCCCCC(=O)O)O1 XTNOEYFQXCQKLC-UHFFFAOYSA-N 0.000 claims 2
- AVUQWNIWFSWLIY-UHFFFAOYSA-N 2,3-dihydroxyicosa-2,4,6-trienoic acid Chemical compound CCCCCCCCCCCCCC=CC=CC(O)=C(O)C(O)=O AVUQWNIWFSWLIY-UHFFFAOYSA-N 0.000 claims 2
- 108020002908 Epoxide hydrolase Proteins 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 102100025357 Lipid-phosphate phosphatase Human genes 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000011623 Obstructive Lung disease Diseases 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 238000010276 construction Methods 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 claims 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims 1
- 208000006029 Cardiomegaly Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 150000003573 thiols Chemical class 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462043275P | 2014-08-28 | 2014-08-28 | |
| US62/043,275 | 2014-08-28 | ||
| PCT/US2015/046878 WO2016033150A1 (en) | 2014-08-28 | 2015-08-26 | Soluble epoxide hydrolase inhibitors and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017525777A JP2017525777A (ja) | 2017-09-07 |
| JP2017525777A5 true JP2017525777A5 (enExample) | 2018-09-27 |
Family
ID=55400481
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017530962A Pending JP2017525777A (ja) | 2014-08-28 | 2015-08-26 | 可溶性エポキシドヒドロラーゼ阻害剤及びこれらの使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US10081616B2 (enExample) |
| EP (1) | EP3186228A4 (enExample) |
| JP (1) | JP2017525777A (enExample) |
| CN (2) | CN107074771B (enExample) |
| AU (2) | AU2015306643B2 (enExample) |
| CA (1) | CA2958881A1 (enExample) |
| MA (1) | MA40538A (enExample) |
| WO (1) | WO2016033150A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017525777A (ja) * | 2014-08-28 | 2017-09-07 | エックス−ケム，インコーポレーテッド | 可溶性エポキシドヒドロラーゼ阻害剤及びこれらの使用 |
| EP3600266B1 (en) * | 2017-03-30 | 2022-07-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Pharmaceutical compositions for use in the treatment of cardiovascular calcification |
| US20230071934A1 (en) * | 2019-12-18 | 2023-03-09 | Intra-Cellular Therapies, Inc. | Novel uses |
| WO2024105225A1 (en) | 2022-11-18 | 2024-05-23 | Universitat De Barcelona | Synergistic combinations of a sigma receptor 1 (s1r) antagonist and a soluble epoxide hydrolase inhibitor (sehi) and their use in the treatment of pain |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3245950A1 (de) * | 1981-12-24 | 1983-07-07 | Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz | Verfahren zur herstellung substituierter pyridine |
| AR037233A1 (es) * | 2001-09-07 | 2004-11-03 | Euro Celtique Sa | Piridinas aril sustituidas, composiciones farmaceuticas y el uso de dichos compuestos para la elaboracion de un medicamento |
| US20040067985A1 (en) * | 2002-10-04 | 2004-04-08 | Fortuna Haviv | Method of inhibiting angiogenesis |
| JP2009528992A (ja) * | 2006-02-16 | 2009-08-13 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 可溶性エポキシド加水分解酵素阻害剤として有益な置換ピリジンアミン化合物 |
| CA2643859A1 (en) | 2006-03-10 | 2007-09-20 | Boehringer Ingelheim International Gmbh | Soluble epoxide hydrolase inhibitors and methods of using same |
| CN102516115B (zh) * | 2006-08-09 | 2016-05-11 | 史密丝克莱恩比彻姆公司 | 作为阿片样物质受体的拮抗剂或反向激动剂的新型化合物 |
| CA2672373C (en) * | 2006-12-19 | 2011-08-30 | Pfizer Products Inc. | Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases |
| EP2002834A1 (de) * | 2007-06-13 | 2008-12-17 | Bayer Schering Pharma Aktiengesellschaft | Aryl/Hetarylamide als Modulatoren des EP2-Rezeptors |
| WO2009151800A1 (en) * | 2008-05-07 | 2009-12-17 | Merck & Co., Inc. | Soluble epoxide hydrolase inhibitors, compositions containing such compounds and methods of treatment |
| US20110306597A1 (en) * | 2008-06-18 | 2011-12-15 | James Michael Crawforth | Nicotinamide Derivatives |
| TW201010997A (en) * | 2008-06-18 | 2010-03-16 | Pfizer Ltd | Nicotinamide derivatives |
| EP2149552A1 (de) * | 2008-07-30 | 2010-02-03 | Bayer Schering Pharma AG | 5,6 substituierte Benzamid-Derivate als Modulatoren des EP2-Rezeptors |
| EP2149551A1 (de) * | 2008-07-30 | 2010-02-03 | Bayer Schering Pharma AG | N-(Indol-3-ylalkyl)-(hetero)arylamidderivate als Modulatoren des EP2-Rezeptors |
| US20100113512A1 (en) * | 2008-10-30 | 2010-05-06 | Diane Michele Ignar | Method of treatment using novel antagonists or inverse agonists at opioid receptors |
| WO2010080183A1 (en) | 2009-01-08 | 2010-07-15 | The Trustees Of Columbia University In The City Of New York | Potent non-urea inhibitors of soluble epoxide hydrolase |
| WO2011091410A1 (en) * | 2010-01-25 | 2011-07-28 | Glaxos Smithkline Llc | Trpv4 antagonists |
| US20130102600A1 (en) * | 2011-10-21 | 2013-04-25 | F. Hoffmann-La Roche Ltd | Heteroaryl hydroxamic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease |
| US20130102601A1 (en) * | 2011-10-21 | 2013-04-25 | F. Hoffmann-La Roche Ltd | Pyrimidin-4-one derivatives and their use in the treatment, amelioration or prevention of a viral disease |
| US8809552B2 (en) * | 2011-11-01 | 2014-08-19 | Hoffmann-La Roche Inc. | Azetidine compounds, compositions and methods of use |
| WO2013112751A1 (en) * | 2012-01-25 | 2013-08-01 | The Trustees Of Columbia University In The City Of New York | Potent non-urea inhibitors of soluble epoxide hydrolase |
| KR20150085045A (ko) * | 2012-11-16 | 2015-07-22 | 메르크 파텐트 게엠베하 | 3-아미노시클로펜탄 카르복사미드 유도체 |
| CN104016914B (zh) * | 2014-05-27 | 2016-03-30 | 苏州科技学院 | 一种酰胺化合物的制备方法 |
| JP2017525777A (ja) * | 2014-08-28 | 2017-09-07 | エックス−ケム，インコーポレーテッド | 可溶性エポキシドヒドロラーゼ阻害剤及びこれらの使用 |
-
2015
- 2015-08-26 JP JP2017530962A patent/JP2017525777A/ja active Pending
- 2015-08-26 EP EP15837061.9A patent/EP3186228A4/en not_active Withdrawn
- 2015-08-26 AU AU2015306643A patent/AU2015306643B2/en not_active Ceased
- 2015-08-26 CN CN201580046202.2A patent/CN107074771B/zh not_active Expired - Fee Related
- 2015-08-26 MA MA040538A patent/MA40538A/fr unknown
- 2015-08-26 US US15/504,223 patent/US10081616B2/en not_active Expired - Fee Related
- 2015-08-26 CA CA2958881A patent/CA2958881A1/en not_active Abandoned
- 2015-08-26 CN CN202010138750.0A patent/CN111454246A/zh active Pending
- 2015-08-26 WO PCT/US2015/046878 patent/WO2016033150A1/en not_active Ceased
-
2018
- 2018-08-23 US US16/110,698 patent/US20180362499A1/en not_active Abandoned
-
2020
- 2020-07-22 AU AU2020207828A patent/AU2020207828A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124882T1 (el) | Αναλογα 1,4-διϋποκατεστημενης πυριδαζινης και μεθοδοι για την θεραπευτικη αγωγη καταστασεων συναφων με ανεπαρκεια smn | |
| UA109698C2 (xx) | Похідні азаіндазолу або діазаіндазолу як медикамент | |
| JP2016533366A5 (enExample) | ||
| JP2016506916A5 (enExample) | ||
| RU2013121788A (ru) | Ингибиторы репликации вич | |
| JP2016534063A5 (enExample) | ||
| JP2016506935A5 (enExample) | ||
| MX2009001534A (es) | Preparacion de (r,r)-fenoterol y analogos de (r,r)- o (r,s)-fenoterol y su uso en el tratamiento de insuficiencia cardiaca congestiva. | |
| JP2016510326A5 (enExample) | ||
| RU2013137452A (ru) | Композиции, содержащие расщепляемое ферментами пролекарство оксикодона | |
| JP2017525777A5 (enExample) | ||
| JP2017514910A5 (enExample) | ||
| EA201590735A1 (ru) | 2-фенил-5-гетероциклил-тетрагидро-2h-пиран-3-аминовые соединения для применения в лечении диабета и связанных с ним расстройств | |
| NZ608584A (en) | Substituted n-(2-arylamino)aryl sulfonamide-containing combinations | |
| RU2019141734A (ru) | Терапевтические соединения и композиции и способы их применения | |
| JP2013519653A5 (enExample) | ||
| EP3404029A3 (en) | Pyrimido-pyridazinone compounds and methods and use thereof | |
| JP2015502926A5 (enExample) | ||
| IN2014DN08582A (enExample) | ||
| JP2017519020A5 (enExample) | ||
| RU2011147186A (ru) | 2, 5-дизамещенные арилсульфонамидные антагонисты ссr3 | |
| JP2019516707A5 (enExample) | ||
| BR112015016184A2 (pt) | derivados de piridona e seu uso no tratamento, melhora ou prevenção de uma doença viral | |
| FI3506900T3 (fi) | Ampreloksetiini käytettäväksi neurogeenisen ortostaattisen hypotension | |
| NZ705813A (en) | Treatment of mild and moderate alzheimer’s disease |